Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.32 - $12.70
Previous CloseN/A
Volume8.30K
Average Volume (3M)2.46K
Market Cap
$168.76M
Enterprise Value$66.22M
Total Cash (Recent Filing)CHF63.87M
Total Debt (Recent Filing)CHF2.44M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 25, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding40,374,640
10 Day Avg. Volume4,374
30 Day Avg. Volume2,457
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)31.07
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.50Price Target Upside234.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Molecular Partners News
PremiumCompany Announcements
Molecular Partners AG: Strategic Advances and Financial Overview
PremiumCompany Announcements
Molecular Partners and Orano Med Expand Cancer Therapy Collaboration
PremiumCompany Announcements
Molecular Partners Advances Radio-DARPin Programs with Strong Funding---
Bulls Say, Bears Say
Bulls Say
Partnership And CollaborationThe enhanced partnership with Orano Med includes a co-development agreement, where MOLN will retain commercial rights to MP0712, seen as a positive strategic move.
Technological AdvantageMOLN has made substantial progress in dialing out off-target kidney exposure to its radioligands, further differentiating the RadioDARPin platform from competitors.
Bears Say
Financial PerformanceMolecular Partners Ag reported 3Q24 financial results and provided a pipeline update in line with expectations, highlighting progress in its RDT franchise.
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.32 and its highest was $12.70 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $168.76M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Aug 25, 2025 which is in 162 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Mar 06, 2025. The company reported -$0.341 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.107.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.45.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.341 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 2.245%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
---
Molecular Partners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.50 (234.87% Upside)
$14.50 (234.87% Upside)
Blogger Sentiment
Bullish
MOLN Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.03%
12-Months-Change
Fundamentals
Return on Equity
-33.54%
Trailing 12-Months
Asset Growth
-25.77%
Trailing 12-Months
Company Description
Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
---
MOLN Company Deck
---
MOLN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Molecular Partners' programs, particularly in the radio DARPin franchise and the improved efficacy of the 533-DARPIn program. The expansion of the Orano Med collaboration and strong financial position further bolster the company's outlook. However, the discontinuation of the Novartis collaboration and initial challenges with the T Cell Engager program were noted as setbacks. Overall, the highlights significantly outweigh the lowlights.Read More>---
MOLN Stock 12 Month Forecast
Average Price Target
$14.50
▲(234.87% Upside)
Technical Analysis
Alnylam Pharma
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Argenx Se
―
Best Analysts Covering MOLN
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-19.10%
reiterated a buy rating 5 months ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.10% per trade.
---